Gyre Therapeutics (GYRE)

Executive Summary

Gyre Therapeutics (NASDAQ: GYRE) is a clinical-stage biopharmaceutical company dedicated to developing therapies for chronic liver and metabolic diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. The company's lead candidate, F351, is an oral hepatic-targeted formulation of pirfenidone, which is currently being evaluated in a Phase 2b trial for MASH with liver fibrosis. This represents a significant area of unmet medical need, as MASH affects millions worldwide and has limited treatment options. Gyre's pipeline is concentrated on advancing F351 through clinical development, aiming to address the fibrosis component of the disease, which is a key driver of morbidity and mortality. The company has raised capital through multiple funding rounds to support its R&D activities and is traded on the NASDAQ exchange.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b top-line data readout for F351 in MASH with fibrosis45% success
• Q4 2026Potential partnership or licensing agreement for F351 outside U.S.30% success
• Q2 2026FDA feedback or Fast Track designation update70% success